$25.67
-0.25-0.96%
At Close: -
$25.67
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Royalty Pharma
RPRXNASDAQ
Royalty Pharma (NASDAQ:RPRX) Stock, Analyst Ratings, Price Targets, Forecasts
Royalty Pharma PLC has a consensus price target of $47.11 based on the ratings of 25 analysis. The 3 most-recent analyst ratings were released by UBS, B of A Securities, and JP Morgan on June 3, 2024, April 12, 2024, and February 20, 2024, respectively. With an average price target of $36 between UBS, B of A Securities, and JP Morgan, there's an implied 40.24% upside for Royalty Pharma PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
B of A Securities
JP Morgan
Goldman Sachs
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Royalty Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 9.08% | UBS | Ashwani Verma | → $28 | Downgrade | Buy → Neutral | Get Alert |
| 04/12/2024 | Buy Now | 48.03% | B of A Securities | Geoff Meacham | $40 → $38 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 63.62% | JP Morgan | Chris Schott | $45 → $42 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 94.78% | Goldman Sachs | Chris Shibutani | $56 → $50 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | 122.05% | Morgan Stanley | Terence Flynn | $54 → $57 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | 110.36% | Morgan Stanley | Terence Flynn | $53 → $54 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 106.47% | Morgan Stanley | Terence Flynn | $52 → $53 | Maintains | Overweight | Get Alert |
| 07/11/2023 | Buy Now | 102.57% | Morgan Stanley | Terence Flynn | $52 → $52 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | Buy Now | 102.57% | Morgan Stanley | Terence Flynn | $50 → $52 | Maintains | Overweight | Get Alert |
| 04/10/2023 | Buy Now | 94.78% | Morgan Stanley | Terence Flynn | $48 → $50 | Maintains | Overweight | Get Alert |
| 04/06/2023 | Buy Now | 133.74% | Tigress Financial | Ivan Feinseth | $57 → $60 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | 86.99% | UBS | Ashwani Verma | $51 → $48 | Maintains | Buy | Get Alert |
| 12/06/2022 | Buy Now | 98.68% | Morgan Stanley | Terence Flynn | $54 → $51 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 110.36% | Morgan Stanley | Terence Flynn | $51 → $54 | Maintains | Overweight | Get Alert |
| 10/18/2022 | Buy Now | 102.57% | JP Morgan | Chris Schott | $50 → $52 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 98.68% | Morgan Stanley | Terence Flynn | $48 → $51 | Maintains | Overweight | Get Alert |
| 07/14/2022 | Buy Now | 122.05% | Tigress Financial | Ivan Feinseth | $52 → $57 | Maintains | Buy | Get Alert |
| 06/14/2022 | Buy Now | 83.09% | UBS | Ashwani Verma | → $47 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | 106.47% | Scotiabank | Adam Buckham | → $53 | Initiates | → Outperform | Get Alert |
| 04/27/2022 | Buy Now | 118.15% | Goldman Sachs | Chris Shibutani | → $56 | Initiates | → Buy | Get Alert |
| 04/14/2022 | Buy Now | 94.78% | JP Morgan | Chris Schott | → $50 | Upgrade | Neutral → Overweight | Get Alert |
| 04/06/2022 | Buy Now | 86.99% | Morgan Stanley | Terence Flynn | $46 → $48 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/29/2021 | Buy Now | 94.78% | Citigroup | Andrew Baum | — | Upgrade | Neutral → Buy | Get Alert |
| 08/16/2021 | Buy Now | 79.2% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 07/30/2021 | Buy Now | 94.78% | Tigress Financial | Ivan Feinseth | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Royalty Pharma (RPRX) stock?
The latest price target for Royalty Pharma (NASDAQ:RPRX) was reported by UBS on June 3, 2024. The analyst firm set a price target for $28.00 expecting RPRX to rise to within 12 months (a possible 9.08% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Royalty Pharma (RPRX)?
The latest analyst rating for Royalty Pharma (NASDAQ:RPRX) was provided by UBS, and Royalty Pharma downgraded their neutral rating.
When was the last upgrade for Royalty Pharma (RPRX)?
The last upgrade for Royalty Pharma PLC happened on April 14, 2022 when JP Morgan raised their price target to $50. JP Morgan previously had a neutral for Royalty Pharma PLC.
When was the last downgrade for Royalty Pharma (RPRX)?
The last downgrade for Royalty Pharma PLC happened on June 3, 2024 when UBS changed their price target from N/A to $28 for Royalty Pharma PLC.
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Royalty Pharma (RPRX) correct?
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a downgraded with a price target of $0.00 to $28.00. The current price Royalty Pharma (RPRX) is trading at is $25.67, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.